European Journal of Cancer
Volume 39, Issue 7 , Pages 917-926 , May 2003

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

  • F.A.L.M Eskens

      Affiliations

    • Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-10-463-4897; fax: +31-10-463-4627
    • ,
  • H Dumez

      Affiliations

    • University Hospital Gasthuisberg, 3000 Leuven, Belgium
    • ,
  • R Hoekstra

      Affiliations

    • Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • A Perschl

      Affiliations

    • Merck KGaA, D-64293 Darmstadt, Germany
    • ,
  • C Brindley

      Affiliations

    • Quintiles Scotland Limited, Edinburgh EH14 4AP, Scotland, UK
    • ,
  • S Böttcher

      Affiliations

    • Merck KGaA, D-64293 Darmstadt, Germany
    • ,
  • W Wynendaele

      Affiliations

    • University Hospital Gasthuisberg, 3000 Leuven, Belgium
    • ,
  • J Drevs

      Affiliations

    • Tumour Biology Center, Freiburg, Germany
    • ,
  • J Verweij

      Affiliations

    • Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • A.T van Oosterom

      Affiliations

    • University Hospital Gasthuisberg, 3000 Leuven, Belgium

Received 4 July 2002 ,Accepted 21 November 2002.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(03)00057-1

doi: 10.1016/S0959-8049(03)00057-1

European Journal of Cancer
Volume 39, Issue 7 , Pages 917-926 , May 2003

Article Tools

* Image Usage & Resolution